Clinical Study
Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease
Table 1
Demographic and clinical data at baseline.
| | Variable | Bromocriptine | Placebo | value |
| | 14 | 14 | | | Gender (M/F) | 6/8 | 6/8 | | | Age (years) | 61.7 ± 8.8 | 60.4 ± 7.7 | NS | | Evolution time of diabetes (years) | 18.3 ± 2.1 | 17.4 ± 1.6 | NS | | Evolution time of hypertension (years) | 8.9 ± 3.0 | 7.1 ± 1.1 | NS | | Weight (kg) | 67 ± 4 | 64 ± 3 | NS | | Height (m) | 1.6 ± 0.1 | 1.6 ± 0.1 | NS | | BMI (kg/m2) | 26.8 ± 1.2 | 25.9 ± 1.5 | NS | | SBP (mmHg) | 177 ± 20 | 174 ± 22 | NS | | DBP (mmHg) | 101 ± 8 | 99 ± 7 | NS | | Heart rate (beats/minute) | 80.7 ± 6.7 | 80.0 ± 2.2 | NS | | LVMI (g/m2) | 143.9 ± 23.1 | 146.2 ± 27.6 | NS | | CrCl (mL/min) | 16.8 ± 7.7 | 17.7 ± 4.3 | NS | | Glucose (mmol/L) | 8.16 ± 0.95 | 7.23 ± 0.93 | NS | | Cholesterol (mmol/L) | 5.65 ± 0.33 | 5.82 ± 0.48 | NS | | Triglycerides (mmol/L) | 2.39 ± 0.22 | 2.25 ± 0.32 | NS | | Hemoglobin (mmol/L) | 7.24 ± 0.24 | 7.14 ± 0.24 | NS | | Hematocrit (%) | 34.98 ± 1.04 | 34.92 ± 1.19 | NS |
|
|
SBP: systolic blood pressure; DBP: diastolic blood pressure; LVMI: left ventricular mass index; CrCl: creatinine clearance.
|
